The role of botulinum toxin in vasospastic disorders of the hand

Hand Clinics

Volumn 31, Issue 1, 2015, Pages 23-37

  Neumeister, Michael W ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Botox; Botulinum toxin; Ischemia; Pain; Raynaud; Vasodilation; Vasospasm

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTIOXIDANT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN DERIVATIVE; RHO KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VASODILATOR AGENT; BOTULINUM TOXIN A; CARDIOVASCULAR AGENT; MUSCLE RELAXANT AGENT;

BLOOD VESSEL TONE; CLINICAL FEATURE; CYANOSIS; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ERYTHEMA; HUMAN; PALLOR; PHYSICAL EXAMINATION; RAYNAUD PHENOMENON; REVIEW; VASOCONSTRICTION; VASODILATATION; DRUG EFFECTS; HAND; ISCHEMIA; PATHOPHYSIOLOGY; RAYNAUD DISEASE; VASCULARIZATION;

BOTULINUM TOXINS, TYPE A; CARDIOVASCULAR AGENTS; HAND; HUMANS; ISCHEMIA; NEUROMUSCULAR AGENTS; RAYNAUD DISEASE; VASOCONSTRICTION;

EID: 84921845587     PISSN: 07490712     EISSN: 15581969     Source Type: Journal    
DOI: 10.1016/j.hcl.2014.09.003     Document Type: Review

References (80)

1. Bakst R., Merola J.F., Franks A.G., et al. Raynaud's phenomenon: pathogenesis and management. JAm Acad Dermatol 2008, 59(4):633-653.
2. de Trafford J.C., Lafferty K., Potter C.E., et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988, 2:167-170.
3. Department of Health and Human Services, Public Health Service, National Institutes of Health, et al. Questions and answers about Raynaud's phenomenon 2001, NIH, Publication No. 06-4911, Revised June 2006. Available at:. http://vickiehonea.com/raynaudsRP_04.pdf.
4. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega R.O., et al. Treatment of Raynaud's phenomenon. Autoimmun Rev 2008, 8:62-68.
5. Bowling J.C., Dowd P.M. Raynaud's disease. Lancet 2003, 361:2078-2080.
6. Fonseca C., Abraham D., Ponticos M. Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis. Curr Vasc Pharmacol 2009, 7(1):34-39.
7. Ramien M., Brassard A. The challenge of scleroderma ulcers. JCutan Med Surg 2009, 13(Suppl 1):S42-S48.
8. Nihtgyanova S.I., Brough G.M., Black C.M., et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008, 67(1):120-123.
9. Morris J.L., Jobling P., Gibbins I.L. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001, 28:H2124-H2132.
10. Silveri F., De Angelis R., Poggi A., et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001, 30:290-296.
11. Rosato E., Letizia C., Proietti M., et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. JBiol Regul Homeost Agents 2009, 23:23-29.
12. Durham P.L., Cady R., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004 Jan, 44(1):35-42. [discussion: 42-3].
13. Edwards C.M., Marshall J.M., Pugh M. Cardiovascular responses evoked mild cool stimuli in primary Raynaud's disease: the role of endothelin. Clin Sci 1999, 96:577.
14. Freedman R.R., Girgis R., Mayes M. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. JRheumatol 1999, 26(11):2386-2388.
15. Lazzerini P.E., Capecchi P.L., Bisogno S., et al. Homocysteine and Raynaud's phenomenon: a review. Autoimmun Rev 2010, 9:181-187.
16. Leppert J., Ringqvis A., Ahlner J. Seasonal variations in cyclic GMP response on whole-body cooling in women with primary Raynaud's phenomenon. Clin Sci 1997, 93:175.
17. McMahon H.T., Foran P., Dolly J.O., et al. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. JBiol Chem 1992, 267(30):21338-21343.
18. Muller-Ladner U., Distler O., Ibba-Manneschi L., et al. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity Oct 2009, 42(7):587-595.
19. Duprez D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. JHypertens 2006, 24:983-991.
20. Kawaguchi Y., Takagi K., Hara M., et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheumatol 2004, 50:216-226.
21. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
22. Flavahan N.A., Vanhoutte P.M. Endothelial cell signaling and endothelial dysfunction. Am J Hypertens 1995, 8(Suppl):28S-41S.
23. Droste H., Wollersheim H., Reyenga J., et al. Vascular and humoral sympathetic nervous system reactively during mental arithmetic in primary Raynaud's phenomenon. Int Angiol 1990, 9:84-89.
24. Bunker C.B., Goldsmith P.C., Leslie T.A., et al. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996, 134:399-406.
25. Bunker C.B., Terenghi G., Springall D.R., et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990, 336:1530-1533.
26. Bunker C.B., Reavlety C., O'Shaughnessy D.J., et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993, 342:80-83.
27. Generini S., Seibold J.R., Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005, 31:177-186.
28. Chotani M.A., Flavahan S., Mitra S., et al. Silent alpha (2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000, 278:H1075-H1083.
29. Bailey S.R., Eid A.H., Mitra S., et al. Rho kinase mediates cold-induced construction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004, 94:1367-1374.
30. Bailey S.R., Mitra S., Flavahan S., et al. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005, 289:H243-H250.
31. Furspan P.B., Chatterjee S., Freedman R.R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increase vascular reactivity of Raynaud's disease. Arthritis Rheum 2004, 50:1578-1585.
32. Furspan P.B., Chatterjee S., Mayes M.D., et al. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology 2005, 44:488-494.
33. Lau C.S., McLaren M., Saniabadi A., et al. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993, 22:97-101.
34. LeRoy E.C. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996, 22:675-694.
35. Flavahan N.A., Flavahan S., Mitra S., et al. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003, 29:275-291.
36. Henness S., Wigley F.M. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007, 19(6):611-618.
37. Lambova S.N., Muller-Ladner U. New lines in therapy of Raynaud's phenomenon. Rheumatol Int 2009, 29:355-363.
38. Neumeister M.W., Chambers C.B., Herron M.S., et al. Botox therapy for ischemic digits. Plast Reconstr Surg 2009, 124(1):191-201.
39. Van Beek A.L., Lim P.K., Gear A.J.L., et al. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007, 119:217.
40. Fregene A., Ditmars D., Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. JHand Surg Am 2009, 34(3):446-452.
41. Koman L.A., Smith B.P., Smith T.L. Vascular disorders. Greens operative hand surgery 1999, 2254-2302. Churchill Livingstone, New York. D.P. Green, R.N. Hotchkiss, W.C. Pederson (Eds.).
42. Baumhaekel M., Scheffler P., Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005, 69(3):178-179.
43. Baak S.W. Treatment of Raynaud's phenomena with PDE-5 inhibitors, Cialis (tadalafil) in patients with scleroderma and lupus. Arthritis Rheum 2005, 52(Suppl 9):S169.
44. Cheung G.T., Lau C.S., Kumana C.R. Phosphodiesterase 5-inhibitors relieve symptoms of severe Raynaud's phenomenon. Ann Rheum Dis 2004, 64(Suppl 2):211.
45. Colglazier C.L., Sutej P.G., O'Rourke K.S. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. JRheumatol 2005, 32(12):2440-2442.
46. Caglayan E., Huntgeburth M., Karasch T., et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud's disease. Arch Intern Med 2006, 166:231-233.
47. Carlino G. Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor. Ann Rheum Dis 2005, 64(Suppl 3):258.
48. Sandorfi N., Jimenez S.A. Treatment of digital ulceration due to Raynaud's phenomenon (RP) with long acting phosphodiesterase 5 (PDE5) inhibitors: tadalafil. Ann Rheum Dis 2007, 66(Suppl 2):223.
49. Kumar N., Griffiths B., Allen J. Thermographic and symptomatic effects of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment. JRheumatol 2006, 33(9):1918-1919.
50. Kamata Y., Kamimura T., Iwamoto M., et al. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 2005, 30:435-456.
51. Lin C.S., Lin G., Xin Z.C., et al. Expression, distribution, and regulation of phosphodiesterase 5. Curr Pharm Des 2006, 12:3439-3457.
52. Pakozdi A., Howell K., Black C.M., et al. Addition of the short term phosphodiesterase-5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy. Arthritis Rheum 2007, 56(Suppl):825.
53. Schiopu E., Hsu V.M., Impens A.J., et al. Controlled trial of tadalafil in Raynaud's phenomenon (RP) secondary to systemic sclerosis. Arthritis Rheum 2006, 54(Suppl 2):505.
54. Zamiri B., Koman A.L., Smith B.P., et al. Double-blind, placebo-controlled trail of sildenafil for the management of primary Raynaud's phenomenon. Ann Rheum Dis 2004, 63(Suppl3):342.
55. Snipe P.T., Sommer H. Studies on Botulinus toxin: 3. Acid precipitation of Botulinus toxin. JInfect Dis 1928, 43(2):152-160.
56. Burgen A.S., Dickens F., Zatman L.J. The action of botulinum toxin on the neuromuscular junction. JPhysiol 1949, 109(1-2):10-24.
57. Setler P. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002, 18(6):S119-S124.
58. Cheng C.M., Chen J.S., Patel R.P. Unlabled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm 2006, 63(2):145-152.
59. Aoki K.R. Pharmacology and immunology of botulinum toxin serotypes. JNeurol 2001, 248(Suppl 1):3-10.
60. Neumeister M.W. Botulinum toxin type A in the treatment of Raynaud's phenomenon. JHand Surg 2010, 35A:2085-2092.
61. Neumeister M.W., Webb K.N., Romanelli M. Minimally invasive treatment of Raynaud's phenomenon: the role of botulinum type A. Hand Clin 2014, 30:17-34.
62. Sycha T., Graninger M., Auff E., et al. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest 2004, 34:312-313.
63. Cui M., Khanijou S., Rubino J., et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
64. Devor M., Wall P.D. Cross-excitation in dorsal rootganglia of nerve-injured and intact rats. JNeurophysiol 1990, 64(6):1733-1746.
65. Halperin J.L., Cohen R.A., Coffman J.D. Digital vasodilatation during mental stress in patients with Raynaud's disease. Cardiovasc Res 1983, 17:671-677.
66. Colhado O.C., Boeing M., Ortega L.B. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009, 59(3):366-381.
67. Martinez R.M., Saponaro A., Dragagna G., et al. Cutaneous circulation in Raynaud's phenomenon during emotional stress: a morphological and functional study using capillaroscopy and laser-Doppler. Int Angiol 1992, 11:316-320.
68. Fathi M., Fathi H., Mazloumi M., et al. Preventive effect of botulinum toxin A in microanastomotic thrombosis: a rabbit model. JPlast Reconstr Aesthet Surg 2010, 63(10):e720-e724.
69. Janz B.A., Thomas P.R., Fanua S.P., et al. Prevention of anastomotic thrombosis by botulinum toxin B after acute injury in a rat model. JHand Surg Am 2011, 36(1):1585-1591.
70. Park B.Y., Kim H.K., Kim W.S., et al. The effect of botulinum toxin B pretreatment to the blood flow in the microvascular anastomosis. Ann Plast Surg 2014, 72(2):214-219.
71. Murakami E., Iwata H., Imaizumi M., et al. Prevention of arterial graft spasm by botulinum toxin: an in-vitro experiment. Interact Cardiovasc Thorac Surg 2009, 9(3):395-398.
72. Clemens M.W., Higgins J.P., Wilgis E.F. Prevention of anastomotic thrombosis by botulinum toxin-A in an animal model. Plast Reconstr Surg 2009, 123(1):64-70.
73. Upton J., Garcia J., Liao E. Botox to the rescue. Plast Reconstr Surg 2009, 123(1):38e.
74. Kim Y.S., Roh T.S., Lee W.J., et al. The effect of botulinum toxin A on skin flap survival in rats. Wound Repair Regen 2009, 17(3):411-417.
75. Arnold P.B., Merritt W., Rodeheaver G.T., et al. Effects of perivascular botulinum toxin-A application on vascular smooth muscle and flap viability in the rat. Ann Plast Surg 2009, 62(5):463-467.
76. Arnold P.B., Fang T., Songcharoen S.J., et al. Inflammatory response and survival of pedicled abdominal flaps in a rat model after perivascular application of botulinum toxin type A. Plast Reconstr Surg 2014, 133(4):491e-498e.
77. Schweizer D.F., Schweizer R., Zhang S., et al. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. JSurg Res 2013, 184:1205-1213.
78. Stone A.V., Koman L.A., Callahan M.F., et al. The effect of botulinum neurotoxin A on blood flow in rats: a potential mechanism for the treatment of Raynaud's phenomenon. JHand Surg 2012, 37(4):795-802.
79. Borodic G. Immunologic resistance after repeated botulinum toxin A injections for facial rhytids. Ophthal Plast Reconstr Surg 2006, 6(22):239.
80. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994, 9:213.